HMA Launches its Newsletter to provide updates about its coordinated work in the European regulatory network

• The Heads of Medicines Agencies (HMA) has launched its first official newsletter to keep stakeholders informed on key regulatory developments, collaborations, and strategic updates across the European medicines network.
• Interested stakeholders can subscribe to this newsletter at HMA website 

The Heads of Medicines Agencies (HMA) is proud to announce the launch of the first issue of its official newsletter – your go-to source for key updates, expert insights, and strategic developments across the European regulatory network.

This newsletter is carefully crafted to provide readers with regulatory updates and news, interviews with national experts, upcoming events and webinars, and educational resources and tools. According to Maria Jesus Lamas, head of HMA Management Group, “This newsletter reflects our commitment to transparency, collaboration and future-oriented regulation. It’s more than just updates – it’s a shared space for learning and shaping what’s next.” 

The inaugural edition will cover a variety of topics, including a joint HMA-EMA statement on unregulated advanced therapy medicinal products (ATMPs), the newly published European Medicines Agencies Network Strategy (EMANS) to 2028, and the release of the EU-Innovation Network’s workplan. It also features updates from key regulatory groups, including revisions to the cover letter template for clinical trial applications, developments in veterinary drug procedures, new nominations within HMA, and HMA’s participation in DIA Europe 2025.

To subscribe and read the full issue, visit https://www.hma.eu/about-hma/newsletter.html .